Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NM-198
- Development stage
- Preclinical
- Lead developer
- Speratum Biopharma
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NM-198 is a novel RNA interference (RNAi)-based therapeutic candidate developed by Speratum Biopharma, Inc. It harnesses the tumor-suppressing power of microRNA miR-198 to target multiple oncogenic pathways involved in cancer progression. The drug acts as a mesothelin (MSLN) inhibitor through RNA interference mechanisms, downregulating factors such as Valosin-containing protein (VCP) that are implicated in autophagy and drug resistance in pancreatic ductal adenocarcinoma (PDAC). NM-198 is delivered using Speratum’s proprietary Nano-In™ nanoparticle platform combined with the NoPass™ technology for enhanced targeting specificity and reduced off-target effects. Preclinical studies have shown that NM-198 sensitizes resistant pancreatic cancer models to gemcitabine chemotherapy, significantly reducing tumor growth and metastasis. The therapy aims to overcome multi-drug resistance by disrupting autophagy maturation and other key cancer pathways[1][2][4][5].
- Other names
- miR-198miR198miR 198
02
Targets
Valosin-containing protein (VCP) mRNAMesothelinMELTF (Melanotransferrin)
Beyond the preview
Go deeper on NM-198.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NM-198.